Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Alibaba

Discovery

International Flavors & Fragrances

Unilever

KLA-Tencor

Nucor

Auxier Asset Management leader Jeff Auxier (Trades, Portfolio) released his first-quarter portfolio earlier this week.

Jeff Auxier's Top 5 Trades of the 1st Quarter

WARSAW, Ind., May 19, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at Bernstein's 37th Annual Strategic Decisions Conference on Wednesday, June 2, 2021, at 10:00 a.m.

Zimmer Biomet to Present at Bernstein's 37th Annual Strategic Decisions Conference and the Jefferies Virtual Health Care Conference

As elective surgery candidates return to operating rooms, revenue will ramp up.

1 More Excellent Reason to Love This Leading Healthcare Company

Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.

Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic

Zimmer Biomet Holdings Inc (NYSE: ZBH) shares took a hit today despite first-quarter results beating the consensus. Adjusted diluted EPS of $1.71, grew 0.6% Y/Y, and surpassed Wall Street's estimate of $1.53.

Zimmer Biomet Stock Dips Despite Q1 Earnings Beat, Better-Than-Expected Guidance

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q1 2021 Results - Earnings Call Transcript

Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.

Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up

Zimmer (ZBH) delivered earnings and revenue surprises of 13.25% and 5.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

WARSAW, Ind., May 4, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2021.

Zimmer Biomet Announces First Quarter 2021 Financial Results and Full Year Revenue Outlook

WARSAW, Ind., April 27, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021, at 12:30 p.m.

Zimmer Biomet to Present at BofA Securities 2021 Virtual Health Care Conference

ConforMIS

Integra LifeSciences Holdings

Orthofix International

SeaSpine Holdings

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

WARSAW, Ind., April 20, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced U.S. Food and Drug Administration 510(k) clearance of the ROSA® Partial Knee System for robotically-assisted partial knee replacement surgeries.

Zimmer Biomet Receives FDA Clearance for ROSA® Partial Knee System for Robotically-Assisted Partial Knee Arthroplasty

WARSAW, Ind., April 6, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Tuesday, May 4, 2021 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2021 Financial Results

Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.

Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite

WARSAW, Ind., March 31, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today introduced ZBEdge™ Connected Intelligence Suite of currently available and soon to be launched digital and robotic technologies.

Zimmer Biomet Introduces ZBEdge™ Connected Intelligence Suite of Integrated Robotics and Digital Health Technologies

WARSAW, Ind., March 19, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Ivan Tornos has been appointed to the newly-created position of Chief Operating Officer.

Zimmer Biomet Expands Role for Ivan Tornos, Appointing Him to New Chief Operating Officer Post

For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.

Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA

WARSAW, Ind., March 11, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2021.

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2021

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Why Is Zimmer (ZBH) Down 1.4% Since Last Earnings Report?

In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.

Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q4 2020 Results - Earnings Call Transcript

Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.

Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio

Shares of Zimmer Biomet Holdings (NYSE:ZBH) rose 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 8.26% over the past year to $2.11, which beat the estimate of $2.06.

Zimmer Biomet: Q4 Earnings Insights

WARSAW, Ind., Feb. 5, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced its intention to spin off the Company's Spine and Dental businesses to form a new and independent, publicly traded company ("NewCo")....

Zimmer Biomet Announces Intent to Spin Off Spine and Dental Businesses

WARSAW, Ind., Feb. 5, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2020. The Company reported fourth quarter net sales of $2.085 billion, a decrease of 1.9% from the prior year period,...

News for Zimmer Biomet Hlds Stock (ZBH)